Literature DB >> 33063223

Temporal trend in inpatient mortality in inflammatory bowel disease-associated colorectal cancer vs non-inflammatory colorectal cancer: a nationwide retrospective study.

Estefania Flores1, Chimezie Mbachi2, Ikechukwu Achebe3, Jennifer Asotibe3, Emmanuel Palomera-Tejeda3, Ishaan Vohra3, Victor Udechukwu3, Vikram Kotwal4.   

Abstract

BACKGROUND: Early detection and advancement in therapy have successfully achieved a steady decrease in colorectal cancer (CRC) mortality over the last two decades. On the other hand, studies investigating mortality trends in inflammatory bowel disease-associated CRC (IBD-CRC) are scarce and inconclusive. We conducted a retrospective analysis aiming to identify differences between inpatient mortality trends in IBD-CRC vs non-IBD-CRC and possible contributing factors.
METHODS: The National Inpatient Sample (NIS) database from 2006-2014 was queried to identify all patients admitted with a diagnosis of CRC. The main outcome was the prevalence and trend of mortality among IBD-CRC and non-IBD-CRC. The secondary outcome was the evaluation of predictors of inpatient mortality.
RESULTS: A total of 1,190,759 weighted cases with the admission diagnosis of CRC were included in the study. Of which 10,997 (0.9%) had a co-diagnosis of IBD. The population with non-IBD-CRC had a statistically significant downward temporal trend in mortality (p < 0.001), while patients with IBD-CRC did not have any statistically significant temporal trend in inpatient mortality (p = 0.067). After subgroup analysis, patients with Crohn's disease-CRC had an upward temporal trend in mortality (p = 0.183) compared to patients with ulcerative colitis-CRC with a downward trend in mortality (p = 0.001). Sepsis resulted to be a stronger predictor of mortality for CD-CRC, while VTE for UC-CRC.
CONCLUSION: Multiples strategies established to prevent morbidity and mortality in CRC have been fruitful in non-IBD-CRC population, but have not been enough for IBD-CRC population to cause the same effect. Further strategies are needed to achieve a reduction in IBD-CRC mortality trend.

Entities:  

Keywords:  Crohn’s disease-associated colorectal cancer; Inflammatory bowel disease-associated colorectal cancer; Mortality in inflammatory bowel disease; Ulcerative colitis-associated colorectal cancer

Mesh:

Year:  2020        PMID: 33063223     DOI: 10.1007/s00384-020-03775-9

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  21 in total

1.  Effects of cancer treatment on inflammatory bowel disease remission and reactivation.

Authors:  Jordan E Axelrad; Sharyle A Fowler; Sonia Friedman; Ashwin N Ananthakrishnan; Vijay Yajnik
Journal:  Clin Gastroenterol Hepatol       Date:  2012-06-23       Impact factor: 11.382

2.  AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease.

Authors:  Francis A Farraye; Robert D Odze; Jayne Eaden; Steven H Itzkowitz; Robert P McCabe; Themistocles Dassopoulos; James D Lewis; Thomas A Ullman; Tom James; Robin McLeod; Lawrence J Burgart; John Allen; Joel V Brill
Journal:  Gastroenterology       Date:  2010-02       Impact factor: 22.682

Review 3.  Preventing infective complications in inflammatory bowel disease.

Authors:  Justine Mill; Ian C Lawrance
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

4.  Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years.

Authors:  Tine Jess; Jacob Simonsen; Kristian Tore Jørgensen; Bo Vestergaard Pedersen; Nete Munk Nielsen; Morten Frisch
Journal:  Gastroenterology       Date:  2012-04-19       Impact factor: 22.682

Review 5.  Colorectal cancer in inflammatory bowel disease: review of the evidence.

Authors:  D S Keller; A Windsor; R Cohen; M Chand
Journal:  Tech Coloproctol       Date:  2019-01-30       Impact factor: 3.781

Review 6.  Dysplasia and colorectal cancer in inflammatory bowel disease: a result of inflammation or an intrinsic risk?

Authors:  C Breynaert; S Vermeire; P Rutgeerts; G Van Assche
Journal:  Acta Gastroenterol Belg       Date:  2008 Oct-Dec       Impact factor: 1.316

7.  Global patterns and trends in colorectal cancer incidence and mortality.

Authors:  Melina Arnold; Mónica S Sierra; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  Gut       Date:  2016-01-27       Impact factor: 23.059

8.  Forty-Year Analysis of Colonoscopic Surveillance Program for Neoplasia in Ulcerative Colitis: An Updated Overview.

Authors:  Chang-Ho Ryan Choi; Matthew D Rutter; Alan Askari; Gui Han Lee; Janindra Warusavitarne; Morgan Moorghen; Siwan Thomas-Gibson; Brian P Saunders; Trevor A Graham; Ailsa L Hart
Journal:  Am J Gastroenterol       Date:  2015-03-31       Impact factor: 10.864

Review 9.  Colorectal cancer surveillance in inflammatory bowel disease: Practice guidelines and recent developments.

Authors:  William T Clarke; Joseph D Feuerstein
Journal:  World J Gastroenterol       Date:  2019-08-14       Impact factor: 5.742

Review 10.  Reduced Risk of Inflammatory Bowel Disease-associated Colorectal Neoplasia with Use of Thiopurines: a Systematic Review and Meta-analysis.

Authors:  Zhehui Zhu; Zubing Mei; Yuegui Guo; Guanghui Wang; Tingyu Wu; Ximao Cui; Zhenyu Huang; Yilian Zhu; Dongpeng Wen; Jinglve Song; Hailan He; Weimin Xu; Long Cui; Chenying Liu
Journal:  J Crohns Colitis       Date:  2018-04-27       Impact factor: 9.071

View more
  1 in total

1.  Inhibition of the Occurrence and Development of Inflammation-Related Colorectal Cancer by Fucoidan Extracted from Sargassum fusiforme.

Authors:  Xiang Li; Shijun Xin; Xiaoqun Zheng; Liqin Lou; Shiqing Ye; Shengkai Li; Qilong Wu; Qingyong Ding; Ling Ji; Chunrong Nan; Yongliang Lou
Journal:  J Agric Food Chem       Date:  2022-07-20       Impact factor: 5.895

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.